^
    Back
    Association details:
    Biomarker:HR positive
    Cancer:Male Breast Cancer
    Drug:tamoxifen (Estrogen receptor antagonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ASCO.org
    Title:

    Management of Male Breast Cancer: ASCO Guideline

    Published date:
    02/14/2020
    Excerpt:
    Recommendation...Men with hormone receptor–positive breast cancer who are candidates for adjuvant endocrine therapy should be offered tamoxifen (Type: formal consensus; Evidence quality: low; Strength of recommendation: strong).
    DOI:
    10.1200/JCO.19.13120